A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT01925157
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3090106 in healthy participants and in participants with RA who are having an inadequate response to methotrexate (MTX). The study will investigate how the body processes the study drug and how the study drug affects the body. The study will last about 3 months for each participant.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Number of Participants with One or More Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration Baseline through 12 weeks
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3090106 Predose through 12 Weeks Number of Participants with Anti-LY3090106 Antibodies Baseline through 12 Weeks Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3090106 Predose through 12 Weeks
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇷🇴Bucharest, Romania
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.🇷🇴Bucharest, Romania